Aeon biopharma receives notice of allowance from uspto for a patent covering use of botulinum toxins to treat migraine headache

Irvine, calif., aug. 24, 2023 (globe newswire) -- aeon biopharma, inc. (“aeon” or the “company”) (nyse: aeon, aeon ws), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced that it has received a notice of allowance from the united states patent and trademark office (“uspto”) for u.s. patent application no. 17/006,685, titled “neurotoxin compositions for use in treating headache” (the “application”), which involves the company's lead asset, abp-450 (prabotulinumtoxina) injection. the soon to issue patent will provide protection in the united states for the claimed methods of use of abp-450 into 2041.
AEON Ratings Summary
AEON Quant Ranking